Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 150 results for multiple sclerosis

  1. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Register an interest in this interventional procedure NICE has been notified about the above procedure and considered it part of the Ins...

  2. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory notes(if...

  3. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive impairment affects 43–70% of people...

  4. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Spasticity is a common symptom affecting up to 80% of...

  5. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895

      Status ...

  6. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced mobility is one of the most common...

  7. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive...

  8. Types of technology appraisal recommendation

    The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.

  9. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes....

  10. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-TA11391] Expected publication date: 23 October 2024

  11. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis.

  12. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  13. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

  14. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: TBC